Thermo Fisher Scientific Depreciation increased by 10.9% to $306.00M in Q1 2026 compared to the prior quarter.
High depreciation relative to revenue may indicate a capital-intensive business model or significant recent investment in infrastructure.
The systematic allocation of the cost of tangible assets over their useful lives. This non-cash expense reflects the wea...
Standard accounting metric across all capital-intensive industries.
other_depreciation| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $276.00M | $306.00M |
| QoQ Change | — | +10.9% |
| YoY Change | — | +10.9% |
| Segment | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q1 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Laboratory Products and Biopharma Services | — | — | — | — | — | — | $115.00M | $186.00M |
| Life Sciences Solutions | $55.00M | $55.00M | $55.00M | $55.00M | $58.00M | $59.00M | $62.00M | $70.00M |
| Analytical Instruments | $23.25M | $23.25M | $23.25M | $23.25M | $25.00M | $24.00M | $26.00M | $26.00M |
| Specialty Diagnostics | $21.50M | $21.50M | $21.50M | $21.50M | $29.00M | $22.00M | $23.00M | $24.00M |
| Laboratory Productsand Services | $167.25M | $167.25M | $167.25M | — | — | — | — | — |
| Total | — | — | — | — | — | $276.00M | — | $306.00M |
Laboratory Productsand Services is derived from annual filings.
Laboratory Productsand Services was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.